Inform Enrollment
Date of visit
Subject Identification
Inclusion criteria
Signed informed consent
boolean
Male or female; ≥ 20 years (at the time of giving consent)
boolean
Any histologically or cytologically confirmed gastric carcinoma independent of tumor ErbB2 status
boolean
Subjects who have received one prior regimen for gastric carcinoma and developed disease progression or recurrence. The regimen must have contained 5-fluoropyrimidine and/or cisplatin
boolean
Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO). Multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of ≥50% required if normal range of LVEF is not provided by institution)
boolean
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
boolean
Able to swallow and retain oral medication
boolean
Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study
boolean
Washout period from the prior last therapy as follows; Chemotherapy (except for agents below) 4 weeks (I.V) Chemotherapy (except for agents below) 2 weeks (P.O) Trastuzumab, Bevacizumab 4 weeks Mitomycin-C, nitrosourea 6 weeks Radiotherapy, Immunotherapy, Biologic therapy and Surgery (except for minor surgical procedure) 2 weeks
boolean
Willing to complete all screening assessments as outlined in the protocol
boolean
Adequate organ function as defined in Table 2 Baseline Laboratory Values
boolean
Able to be hospitalized for PK analysis during cycle 1
boolean
Life expectancy of at least 12 weeks from the first dose of study treatment)
boolean
Exclusion Criteria
Pregnant or lactating female at anytime during the study
boolean
Planned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment
boolean
Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2)
boolean
Peripheral neuropathy of Grade 2 or greater
boolean
Malabsorption syndrome, disease significantly affecting gastrointestinal function. Subjects with ulcerative colitis and Crohn's disease are also excluded
boolean
History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible
boolean
Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety
boolean
Life threatening infection
boolean
Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
boolean
Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure
boolean
Known history or clinical evidence of central nervous system (CNS) metastasis
boolean
Concurrent treatment with prohibited medications, including herbal remedies and Chinese traditional medicines
boolean
Concurrent treatment with an investigational agent within 28 days prior to the administration of paclitaxel and/or lapatinib
boolean
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel, including polyethoxylated castor oil, alcohol, or lapatinib or their excipients
boolean
Anamnesis or diagnosis of pulmonary disorder, such as interstitial pneumonia, pulmonary fibrosis or serious hypoxia
boolean
Gastrectomy surgery if Pilot Part of the study determines that partial gastrectomy (pylorus spared) or total/partial gastrectomy (pylorus removed) has a significant negative impact upon lapatinib PK and safety profile
boolean
Known history of use of any EGFR agent (except Trastuzumab)
boolean
Prior gastric cancer treatment which included a taxane.
boolean
Eligibility Question
Demography
Date of birth
date
Gender
integer
Ethnicity
integer
Geographic Ancestry
integer
Age